CA2745782C - Pharmaceutical compositions and uses for peptide treatment - Google Patents
Pharmaceutical compositions and uses for peptide treatment Download PDFInfo
- Publication number
- CA2745782C CA2745782C CA2745782A CA2745782A CA2745782C CA 2745782 C CA2745782 C CA 2745782C CA 2745782 A CA2745782 A CA 2745782A CA 2745782 A CA2745782 A CA 2745782A CA 2745782 C CA2745782 C CA 2745782C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- group
- value
- enhancer
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/895,465 | 2004-03-05 | ||
US10/895,465 US7244703B2 (en) | 2001-06-22 | 2004-03-05 | Pharmaceutical compositions and methods for peptide treatment |
CA2566496A CA2566496C (en) | 2004-03-05 | 2005-03-07 | Pharmaceutical compositions and methods for peptide treatment |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2566496A Division CA2566496C (en) | 2004-03-05 | 2005-03-07 | Pharmaceutical compositions and methods for peptide treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2745782A1 CA2745782A1 (en) | 2006-09-14 |
CA2745782C true CA2745782C (en) | 2014-01-21 |
Family
ID=35096491
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2745782A Expired - Fee Related CA2745782C (en) | 2004-03-05 | 2005-03-07 | Pharmaceutical compositions and uses for peptide treatment |
CA2566496A Expired - Fee Related CA2566496C (en) | 2004-03-05 | 2005-03-07 | Pharmaceutical compositions and methods for peptide treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2566496A Expired - Fee Related CA2566496C (en) | 2004-03-05 | 2005-03-07 | Pharmaceutical compositions and methods for peptide treatment |
Country Status (5)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1431919A (zh) * | 2000-04-03 | 2003-07-23 | 巴特勒记忆研究所 | 装置和制剂 |
EP1343521A2 (en) * | 2000-12-01 | 2003-09-17 | Battelle Memorial Institute | Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations |
US8481043B2 (en) * | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
WO2003000158A1 (en) * | 2001-06-22 | 2003-01-03 | Bentley Pharmaceuticals, Inc. | Pharmaceutical composition |
CA2654207A1 (en) * | 2006-06-08 | 2007-12-21 | Cpex Pharmaceuticals, Inc. | Insulin composition |
RU2010114058A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение пептида в качестве терапевтического средства |
WO2009149368A1 (en) * | 2008-06-05 | 2009-12-10 | Cpex Pharmaceuticals, Inc. | Nasal formulations of insulin |
AU2015261630B2 (en) * | 2008-12-22 | 2017-09-14 | Acerus Pharmaceuticals USA, LLC | Intranasal desmopressin administration |
US20100160214A1 (en) * | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
CA2747998C (en) * | 2008-12-22 | 2016-05-31 | Allergan, Inc. | Safe desmopressin administration |
KR101792696B1 (ko) | 2009-06-18 | 2017-11-02 | 알레간 인코포레이티드 | 안전한 데스모프레신 투여 |
US20110097363A1 (en) * | 2009-10-22 | 2011-04-28 | Cpex Pharmaceuticals, Inc. | Therapeutically Effective Preparations of Insulin |
KR101604664B1 (ko) | 2011-10-31 | 2016-03-18 | 제이엑스 닛코닛세키 에네루기 가부시키가이샤 | 졸겔법을 이용한 요철 기판의 제조 방법, 이에 사용하는 졸 용액, 및 이를 사용한 유기 el 소자의 제조 방법과 이로부터 얻어진 유기 el 소자 |
WO2015013453A1 (en) | 2013-07-23 | 2015-01-29 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
DK3024474T3 (da) | 2013-07-23 | 2022-03-28 | Serenity Pharmaceuticals Llc | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist |
US9889087B2 (en) | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
KR20170097045A (ko) | 2014-11-20 | 2017-08-25 | 알레간 인코포레이티드 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
CN113908255A (zh) * | 2021-10-19 | 2022-01-11 | 山西锦波生物医药股份有限公司 | 一种蛋白喷雾剂及其制备方法和用途 |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211766A (en) * | 1972-07-10 | 1980-07-08 | Ab Bonnierforetagen | Cancer associated polypeptide antigen compositions |
CH606154A5 (US07244703-20070717-C00007.png) | 1974-07-02 | 1978-11-15 | Goodrich Co B F | |
CY1410A (en) * | 1979-08-22 | 1988-04-22 | Sandoz Ag | Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
US5132459A (en) * | 1979-08-22 | 1992-07-21 | Sandoz Ltd. | Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
DE3264693D1 (en) * | 1981-12-24 | 1985-08-14 | Ciba Geigy Ag | Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
US4509949A (en) | 1983-06-13 | 1985-04-09 | The B. F. Goodrich Company | Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters |
US4615697A (en) | 1983-11-14 | 1986-10-07 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
US4760096A (en) * | 1985-09-27 | 1988-07-26 | Schering Corporation | Moisturizing skin preparation |
US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
DE3690626C2 (de) | 1985-12-04 | 1997-05-15 | Dean Hsieh | Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton |
DE3544983A1 (de) * | 1985-12-19 | 1987-06-25 | Hoechst Ag | Antimykotisch wirksamer nagellack |
CA1291036C (en) * | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
US4894375A (en) * | 1986-09-29 | 1990-01-16 | Merck & Co., Inc. | Method of controlling mycotic infections and compositions therefor |
US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
US5179079A (en) * | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
US5641475A (en) * | 1987-05-15 | 1997-06-24 | Tristrata, Inc. | Antiodor, antimicrobial and preservative compositions and methods of using same |
LU86924A1 (fr) | 1987-06-19 | 1989-03-08 | Oreal | Vernis a ongles anhydres |
US4983393A (en) * | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
CH672922A5 (US07244703-20070717-C00007.png) | 1987-09-25 | 1990-01-15 | Battelle Memorial Institute | |
US5028431A (en) * | 1987-10-29 | 1991-07-02 | Hercon Laboratories Corporation | Article for the delivery to animal tissue of a pharmacologically active agent |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5118676A (en) * | 1988-04-08 | 1992-06-02 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US4920112A (en) * | 1988-04-18 | 1990-04-24 | Merck & Co., Inc. | Fungicidal compositions and method |
US4920109A (en) * | 1988-04-18 | 1990-04-24 | Merck & Co., Inc. | Antifungal compositions and method of controlling mycotic infections |
US5160737A (en) | 1988-05-03 | 1992-11-03 | Perio Products Ltd. | Liquid polymer composition, and method of use |
US5116603A (en) * | 1989-01-31 | 1992-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Oral antifungal preventative, and method of use |
CA2008775C (en) * | 1989-02-24 | 1998-12-22 | Alberto Ferro | Nail lacquer |
US5214046A (en) * | 1989-07-27 | 1993-05-25 | Hoffmann-La Roche Inc. | Substituted aminoalkoxybenzene anti-fungicidal compositions and use |
CA2020888A1 (en) * | 1989-07-27 | 1991-01-28 | Philippe Guerry | Substituted aminoalkoxybenzene derivatives |
US5562608A (en) | 1989-08-28 | 1996-10-08 | Biopulmonics, Inc. | Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation |
JPH078806B2 (ja) * | 1990-08-16 | 1995-02-01 | 旭化成工業株式会社 | カルシトニン類含有経鼻投与用乳剤 |
FR2666962B1 (fr) | 1990-09-26 | 1996-06-14 | Oreal | Composition antifongique sous forme de spray sec. |
IT1247138B (it) * | 1991-03-06 | 1994-12-12 | Dompe Farmaceutici Spa | Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico. |
FR2673537B1 (fr) * | 1991-03-08 | 1993-06-11 | Oreal | Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes. |
US5437272A (en) * | 1991-05-01 | 1995-08-01 | Alliance Pharmaceutical Corp. | Perfluorocarbon associated gas exchange |
WO1992019232A1 (en) * | 1991-05-03 | 1992-11-12 | Alliance Pharmaceutical Corp. | Partial liquid breathing of fluorocarbons |
US6005001A (en) | 1991-05-20 | 1999-12-21 | Novartis Ag (Formerly Sandoz Ag) | Pharmaceutical composition |
HU223343B1 (hu) * | 1991-05-20 | 2004-06-28 | Novartis Ag. | Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására |
HU219480B (hu) | 1991-05-23 | 2001-04-28 | Novartis Ag. | Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására |
TW246682B (US07244703-20070717-C00007.png) * | 1991-08-12 | 1995-05-01 | Procter & Gamble | |
ATE168569T1 (de) * | 1991-11-14 | 1998-08-15 | Alliance Pharma | Vorrichtung zur teilweisen flüssigen beatmung mit fluorkohlenwasserstoffen |
DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
IT1261776B (it) * | 1993-03-12 | 1996-06-03 | Mendes Srl | Uso di terbinafina per il trattamento terapeutico della pneumocistosi. |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5547661A (en) * | 1994-02-22 | 1996-08-20 | Helene Curtis, Inc. | Antiperspirant deodorant compositions |
US5661170A (en) * | 1994-03-21 | 1997-08-26 | Woodward Laboratories, Inc. | Antimicrobial compositions and methods for using the same |
JP3081766B2 (ja) * | 1994-05-06 | 2000-08-28 | 東興薬品工業株式会社 | 角質貯留型抗真菌外用組成物 |
FR2722102B1 (fr) * | 1994-07-11 | 1996-08-23 | Cird Galderma | Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses |
JPH0827018A (ja) * | 1994-07-22 | 1996-01-30 | Sanwa Kagaku Kenkyusho Co Ltd | 生理活性ペプチド又は蛋白質を含有する薬剤組成物 |
EP0793517B1 (en) | 1994-11-17 | 1999-09-08 | Alza Corporation | Device for enhancing electrotransport agent delivery |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
GB9509631D0 (en) | 1995-05-12 | 1995-07-05 | Sandoz Ltd | Antifungal combination |
US5667809A (en) * | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
FR2735978B1 (fr) * | 1995-06-30 | 1997-09-19 | Sanofi Sa | Composition pharmaceutique d'amiodarone pour administration parenterale |
GB9513750D0 (en) * | 1995-07-06 | 1995-09-06 | Sandoz Ltd | Use of allylamines |
FR2737118B1 (fr) | 1995-07-28 | 1997-09-05 | Oreal | Composition dermatologique ou pharmaceutique, procede de preparation et utilisation |
EP0866683A4 (en) | 1995-09-14 | 1999-01-07 | Sorenson Pharmaceutical Inc | MEANS AND METHOD FOR TREATING DISEASE NAILS |
NZ280065A (en) | 1995-09-20 | 1998-04-27 | Apotex Inc | Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives |
JP3263598B2 (ja) * | 1995-11-01 | 2002-03-04 | 有限会社ドット | 経鼻吸収用生理活性ペプチド組成物 |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
KR100213465B1 (ko) * | 1996-11-01 | 1999-08-02 | 최좌진 | 케토프로펜 패취 조성물 |
US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
US5925616A (en) * | 1996-08-09 | 1999-07-20 | Buckman Laboratories International, Inc. | Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound |
US5993787A (en) | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
ES2260802T3 (es) * | 1996-10-18 | 2006-11-01 | Arizona Chemical Company | Geles de poliamida terminada en esteres. |
US5898028A (en) * | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
US5813416A (en) | 1997-04-03 | 1998-09-29 | Rudolph; James M. | File with sanitizing agent |
US6207142B1 (en) * | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
US5976547A (en) | 1997-04-22 | 1999-11-02 | Niblick Pharmaceuticals, Inc. | Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery |
US6482839B1 (en) | 1997-06-02 | 2002-11-19 | Cellegy Pharmaceuticals, Inc. | Pyridine-thiols for treatment of a follicular dermatosis |
US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US5989535A (en) | 1997-08-15 | 1999-11-23 | Soma Technologies | Polymeric bioadhesive emulsions and suspensions and methods of treatment |
DE69834339T2 (de) * | 1997-08-26 | 2007-05-24 | Board of Regents, The University of Texas System, Austin | Verwendung einer zusammensetzung die einen chelatbildner und eine antimikrobielle verbindung enthaltet zur behandlung von biofilmen |
US6165484A (en) * | 1997-08-26 | 2000-12-26 | Wake Forest University | EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
ES2210808T3 (es) * | 1997-08-27 | 2004-07-01 | California Institute Of Technology | Composiciones y su uso para prevenir la formacion de adherencias en un tejido biologico. |
US5976566A (en) | 1997-08-29 | 1999-11-02 | Macrochem Corporation | Non-steroidal antiinflammtory drug formulations for topical application to the skin |
US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US5968919A (en) | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
BR9814615A (pt) * | 1997-10-22 | 2001-10-16 | Jens Ponikau | Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa |
US6030948A (en) * | 1997-12-19 | 2000-02-29 | Mann; Morris A. | Hair regeneration compositions for treatment of alopecia and methods of application related thereto |
ATE238751T1 (de) * | 1998-02-09 | 2003-05-15 | Macrochem Corp | Antimykotischer nagellack |
US6200951B1 (en) * | 1998-03-12 | 2001-03-13 | Icos Corporation | Chitinase chitin-binding fragments |
US6225075B1 (en) * | 1998-03-13 | 2001-05-01 | Advanced Research And Technology Institute, Inc. | DNA encoding sterol methyltransferase |
US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
NL1008795C2 (nl) * | 1998-04-02 | 1999-10-05 | Rene Werenfridus Lodewijk Vroo | Samenstelling voor het behandelen van hoeven en werkwijze voor het vervaardigen van de samenstelling. |
EP1071409B1 (de) * | 1998-04-14 | 2003-10-15 | BioAgency AG | Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen |
WO1999059543A1 (en) * | 1998-05-20 | 1999-11-25 | Highchem Company., Ltd. | A pharmaceutical formulation for nasal administration |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
US6117119A (en) * | 1998-08-28 | 2000-09-12 | Silipos, Inc. | Gelatinous body protection article having a therapeutic additive |
US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
WO2000062776A1 (fr) | 1999-04-16 | 2000-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Compositions antifongiques |
AU5936400A (en) | 1999-06-04 | 2000-12-28 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
US6403063B1 (en) * | 1999-07-26 | 2002-06-11 | Kenneth I. Sawyer | Method of treating nail fungus |
EP1212093B1 (en) * | 1999-08-26 | 2004-07-07 | Ganeden Biotech, Inc. | Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications |
JP2003509142A (ja) * | 1999-09-15 | 2003-03-11 | アラダイム コーポレーション | 減圧エアロゾル化孔構造 |
US6495124B1 (en) | 2000-02-14 | 2002-12-17 | Macrochem Corporation | Antifungal nail lacquer and method using same |
DE10011081A1 (de) * | 2000-03-09 | 2001-09-13 | Aventis Pharma Gmbh | Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel |
US6281239B1 (en) * | 2000-04-12 | 2001-08-28 | Bradley Pharmeaceuticals, Inc. | Method of treating onychomycosis |
JP4763957B2 (ja) * | 2000-05-10 | 2011-08-31 | オバン・エナジー・リミテッド | メディアミリング |
US6914051B1 (en) * | 2000-06-28 | 2005-07-05 | David M Allen | Penetrating antibiotic gel for soft tissue diseases |
AU8298801A (en) * | 2000-07-26 | 2002-02-05 | John K Vyden | Methods for treating atopic disorders |
US20050032683A1 (en) * | 2000-10-04 | 2005-02-10 | Amento Edward P. | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
EP1201738A1 (en) * | 2000-10-30 | 2002-05-02 | Pfw Aroma Chemicals B.V. | Fragrance composition comprising cyclohexadecanone |
ITMI20010430A1 (it) * | 2001-03-02 | 2002-09-02 | Dinamite Dipharma S P A In For | Metodo per la sintesi di terbinafina |
FR2824147B1 (fr) * | 2001-04-27 | 2004-03-19 | Inst Francais Du Petrole | Methode pour faciliter le suivi au cours du temps de l'evolution d'une zone souterraine par analyse comparee de differents jeux d'enregistrements sismiques |
US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
WO2003000158A1 (en) * | 2001-06-22 | 2003-01-03 | Bentley Pharmaceuticals, Inc. | Pharmaceutical composition |
US6602496B2 (en) * | 2001-07-05 | 2003-08-05 | Closure Medical Corporation | Adhesive treatment for tinea corporis |
US6585967B2 (en) * | 2001-07-05 | 2003-07-01 | Closure Medical Corporation | Adhesive treatment for tinea cruris |
US6673369B2 (en) * | 2001-08-29 | 2004-01-06 | Ranbaxy Laboratories Limited | Controlled release formulation |
MXPA04003179A (es) | 2001-10-04 | 2005-01-25 | Macrochem Corp | Emulsionantes de sal de ibuprofeno y formulaciones de crema que contienen los mismos. |
US20030211995A1 (en) * | 2001-12-21 | 2003-11-13 | Kokai-Kun John Fitzgerald | Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin |
KR100459275B1 (ko) * | 2001-12-28 | 2004-12-03 | 주식회사유한양행 | 터비나핀 또는 그의 염산염의 제조방법 |
CA2487712A1 (en) | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
US6958142B2 (en) * | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
TW200409657A (en) * | 2002-08-08 | 2004-06-16 | Alza Corp | Transdermal vaccine delivery device having coated microprotrusions |
US20030049307A1 (en) * | 2002-08-15 | 2003-03-13 | Gyurik Robert J. | Pharmaceutical composition |
EP1596756A4 (en) * | 2003-01-23 | 2009-11-11 | Supernus Pharmaceuticals Inc | MEANS TO INCREASE ABSORPTION |
CA2534565C (en) * | 2003-08-05 | 2012-06-19 | The Research Foundation Of State University Of New York | Reconstitution medium for protein and peptide formulations |
ATE474591T1 (de) | 2003-12-08 | 2010-08-15 | Cpex Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung |
US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
AU2005247369A1 (en) | 2004-05-10 | 2005-12-08 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
-
2004
- 2004-03-05 US US10/895,465 patent/US7244703B2/en not_active Expired - Lifetime
-
2005
- 2005-03-07 WO PCT/US2005/007449 patent/WO2006096173A1/en active Application Filing
- 2005-03-07 CA CA2745782A patent/CA2745782C/en not_active Expired - Fee Related
- 2005-03-07 EP EP10186116.9A patent/EP2283850B1/en not_active Not-in-force
- 2005-03-07 CA CA2566496A patent/CA2566496C/en not_active Expired - Fee Related
- 2005-03-07 EP EP05724894A patent/EP1773369A4/en not_active Withdrawn
- 2005-03-07 AU AU2005328680A patent/AU2005328680C1/en not_active Ceased
-
2007
- 2007-06-07 US US11/811,304 patent/US7816318B2/en not_active Expired - Fee Related
-
2009
- 2009-09-18 US US12/562,974 patent/US8541359B2/en not_active Expired - Fee Related
-
2011
- 2011-01-18 AU AU2011200188A patent/AU2011200188A1/en not_active Abandoned
-
2013
- 2013-09-11 US US14/024,230 patent/US9358206B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2566496C (en) | 2011-08-30 |
EP1773369A4 (en) | 2008-05-14 |
AU2011200188A1 (en) | 2011-02-03 |
WO2006096173A8 (en) | 2007-04-19 |
US7244703B2 (en) | 2007-07-17 |
CA2745782A1 (en) | 2006-09-14 |
US20100009921A1 (en) | 2010-01-14 |
AU2005328680C1 (en) | 2012-03-15 |
US9358206B2 (en) | 2016-06-07 |
US7816318B2 (en) | 2010-10-19 |
AU2005328680A1 (en) | 2006-09-14 |
EP2283850A1 (en) | 2011-02-16 |
EP1773369A1 (en) | 2007-04-18 |
US20070265191A1 (en) | 2007-11-15 |
CA2566496A1 (en) | 2006-09-14 |
US20140073570A1 (en) | 2014-03-13 |
US8541359B2 (en) | 2013-09-24 |
EP2283850B1 (en) | 2018-04-25 |
AU2005328680B2 (en) | 2011-03-31 |
US20050232867A1 (en) | 2005-10-20 |
WO2006096173A1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2745782C (en) | Pharmaceutical compositions and uses for peptide treatment | |
US8329760B2 (en) | Pharmaceutical composition | |
JP3219096B2 (ja) | n―グリコフロール類及びn―エチレングリコール類を含有する医薬製剤 | |
KR101979051B1 (ko) | 강력한 방출-조절된 제형 | |
KR101586791B1 (ko) | GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 | |
PT1261320E (pt) | Composições farmacêuticas micelares para administração bucal e pulmonar | |
JP2003501404A (ja) | 薬剤の脱水粒子からなる製剤およびこれの調製方法 | |
JP2012006934A (ja) | 口腔及び経肺投与用ミセル薬学的組成物 | |
WO2008096351A1 (en) | Pharmaceutical compositions based on a microemulsion | |
JP6822962B2 (ja) | 制御放出製剤 | |
EP1556004A2 (en) | Pharmaceutical compositions for buccal delivery of pain relief medications | |
Quadir et al. | Development and evaluation of nasal formulations of ketorolac | |
JP2006501220A (ja) | 薬剤の投与及び吸収促進方法 | |
US20230248801A1 (en) | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | |
AU2003263416C1 (en) | Pharmaceutical compositions for buccal delivery of pain relief medications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20210907 |
|
MKLA | Lapsed |
Effective date: 20200309 |